scholarly journals Correction to: Molecular & Diagnostic Imaging in Prostate Cancer

2019 ◽  
pp. E3-E3
Author(s):  
Heide Schatten
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Imaging ◽  
Molecular Diagnostic

Intraoperative Molecular Diagnostic Imaging Can Identify Renal Cell Carcinoma

2016 ◽  
Vol 195 (3) ◽  
pp. 748-755 ◽  
Author(s):  
Thomas J. Guzzo ◽  
Jack Jiang ◽  
Jane Keating ◽  
Elizabeth DeJesus ◽  
Ryan Judy ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Diagnostic Imaging ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Molecular Diagnostic

scholarly journals Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review

2020 ◽  
Vol 21 (15) ◽  
pp. 5484 ◽  
Author(s):  
Tae Jin Kim ◽  
Kyo Chul Koo
Keyword(s):  
Prostate Cancer ◽  
Solid Tumors ◽  
Treatment Modality ◽  
Cytotoxic Agents ◽  
Therapeutic Modality ◽  
Current Status ◽  
Molecular Diagnostic ◽  
Castration Resistant Prostate Cancer ◽  
Androgen Synthesis ◽  
Castration Resistant

The clinical spectrum of prostate cancer (PCa) varies from castration-naive to metastatic castration-resistant disease. Despite the administration of androgen synthesis inhibitors and chemotherapy regimens for castration-resistant prostate cancer, the treatment options for this entity are limited. The utilization of the immune system against cancer cells shows potential as a therapeutic modality for various solid tumors and hematologic malignancies. With technological advances over the last decade, immunotherapy has become an integral treatment modality for advanced solid tumors. The feasibility of immunotherapy has shown promise for patients with PCa, and with advances in molecular diagnostic platforms and our understanding of immune mechanisms, immunotherapy is reemerging as a potential treatment modality for PCa. Various combinations of individualized immunotherapy and immune checkpoint blockers with androgen receptor-targeted therapies and conventional cytotoxic agents show promise. This article will review the current status of immunotherapy, including new discoveries and precision approaches to PCa, and discuss future directions in the continuously evolving landscape of immunotherapy.

Identification of ABCA5 as a tissue and urine diagnostic marker for PIN

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 15508-15508
Author(s):  
M. E. Stearns ◽  
Y. Hu ◽  
M. Wang ◽  
K. A. Veverka
Keyword(s):  
Prostate Cancer ◽  
Electrophoretic Mobility ◽  
Dna Sequence ◽  
Diagnostic Marker ◽  
Early Stage ◽  
Cell Junctions ◽  
Molecular Diagnostic ◽  
Cdna Expression Library ◽  
Gene Encoding ◽  
Highly Sensitive

15508 Background: Bostwick and colleagues have suggested that prostatic intraepithelial neoplasia or PIN is the precursor of prostate cancer, and that a significant percentage of men with PIN develop prostate cancer (Sakr, 1994; Bostwick, 1995b; Arakawa, 1995; Qian, 1995; Qian, 1997). Currently there are no molecular diagnostic markers for PIN. Methods: Recently, we have developed ‘DNA-protein’ binding assays for the identification of novel transcriptional regulatory proteins associated with PIN glands. Electrophoretic mobility shift assays (EMSAs) with the 32P-labeled DNA probe was used for analysis of protein extracts from tissues and urine. Immunolabeling was carried out with rabbit antibodies specific for ABCA5. Results: Electrophoretic mobility assays (EMSAs) revealed that 1 DNA sequence (1 of 4,096 sequences screened) specifically bound a ∼160 Kda protein which was over-expressed in PIN and not found in BPH, SV or PCA glands (n=11). The gene encoding for the 160 Kda protein was cloned from a cDNA expression library by ‘in situ’ hybridization assays with the 32P-labeled DNA sequence. Sequencing revealed that the gene encoding for the 160 Kda protein was ABCA5, a member of the superfamily of ATP-binding cassette (ABC) transporters of multi-drug resistant genes. RT-PCR assays indicated the mRNA was over-expressed in PIN tissue, and was not present in BPH, or SV tissue. Rabbit polyclonal antibodies and immunolabeling showed that the antibodies specifically labeled the cell junctions of 3% glutaraldehyde fixed prostate cells. Immunohistochemistry indicated that ABCA5 was over expressed in foci of intermediate basal cells in normal glands, and in HGPIN. ABCA5 was faintly expressed in PCA glands. Enzyme linked immunoabsorbent assays (ELISAs) demonstrated in blinded studies that ABCA5 was a highly sensitive (>98% sensitivity) urine diagnostic marker for HGPIN in biopsy positive patients (n=107) at a cut off” of 25 ng/ml. ABCA5 was present at very low levels (i.e. <25 ng/ml) in the urine of patients diagnosed with BPH (n=79) or prostatitis or kidney and bladder cancer (>86% specificity). Conclusions: The data suggest that the expression of ABCA5 is over-expressed by PIN and may be a highly sensitive and specific urine diagnostic marker for detection of early stage prostate cancer. No significant financial relationships to disclose.

scholarly journals PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial

Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5795
Author(s):  
Constantinos Zamboglou ◽  
Simon K. B. Spohn ◽  
Sonja Adebahr ◽  
Maria Huber ◽  
Simon Kirste ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Imaging ◽  
Dose Escalation ◽  
Treatment Time ◽  
Imaging Techniques ◽  
Phase Iii ◽  
Tumor Control ◽  
Safe Delivery ◽  
Primary Prostate Cancer ◽  
Psma Pet

Technical advances in radiotherapy (RT) treatment planning and delivery have substantially changed RT concepts for primary prostate cancer (PCa) by (i) enabling a reduction of treatment time, and by (ii) enabling safe delivery of high RT doses. Several studies proposed a dose–response relationship for patients with primary PCa and especially in patients with high-risk features, as dose escalation leads to improved tumor control. In parallel to the improvements in RT techniques, diagnostic imaging techniques like multiparametric magnetic resonance imaging (mpMRI) and positron-emission tomography targeting prostate-specific-membrane antigen (PSMA-PET) evolved and enable an accurate depiction of the intraprostatic tumor mass for the first time. The HypoFocal-SBRT study combines ultra-hypofractionated RT/stereotactic body RT, with focal RT dose escalation on intraprostatic tumor sides by applying state of the art diagnostic imaging and most modern RT concepts. This novel strategy will be compared with moderate hypofractionated RT (MHRT), one option for the curative primary treatment of PCa, which has been proven by several prospective trials and is recommended and carried out worldwide. We suspect an increase in relapse-free survival (RFS), and we will assess quality of life in order to detect potential changes.

scholarly journals Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer

Cancers ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 1371 ◽  
Author(s):  
Bogdan Mitran ◽  
Zohreh Varasteh ◽  
Ayman Abouzayed ◽  
Sara S. Rinne ◽  
Emmi Puuvuori ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Imaging ◽  
Solid Phase ◽  
Solid Phase Peptide Synthesis ◽  
Binding Specificity ◽  
Tumor Uptake ◽  
Biodistribution Data ◽  
Positron Emission ◽  
Ic50 Values

Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) could improve the diagnostic accuracy in prostate cancer (PCa). The aim of this study was to develop a PSMA/GRPR-targeting bispecific heterodimer for SPECT and positron emission tomography (PET) diagnostic imaging of PCa. The heterodimer NOTA-DUPA-RM26 was produced by manual solid-phase peptide synthesis. NOTA-DUPA-RM26 was labeled with 111In and 68Ga, with yields >98%, and demonstrated a high stability and binding specificity to PSMA and GRPR. IC50 values for natIn-NOTA-DUPA-RM26 were 4 ± 1 nM towards GRPR and 824 ± 230 nM towards PSMA. An in vivo binding specificity 1 h pi of 111In-NOTA-DUPA-RM26 in PC3-PIP-xenografted mice demonstrated partially blockable tumor uptake when co-injected with an excess of PSMA- or GRPR-targeting agents. Simultaneous co-injection of both agents induced pronounced blocking. The biodistribution of 111In-NOTA-DUPA-RM26 and 68Ga-NOTA-DUPA-RM26 revealed fast activity clearance from the blood and normal organs via the kidneys. Tumor uptake exceeded normal organ uptake for both analogs 1 h pi. 68Ga-NOTA-DUPA-RM26 had a significantly lower tumor uptake (8 ± 2%ID/g) compared to 111In-NOTA-DUPA-RM26 (12 ± 2%ID/g) 1 h pi. Tumor-to-organ ratios increased 3 h pi, but decreased 24 h pi, for 111In-NOTA-DUPA-RM26. MicroPET/CT and microSPECT/CT scans confirmed biodistribution data, suggesting that 68Ga-NOTA-DUPA-RM26 and 111In-NOTA-DUPA-RM26 are suitable candidates for the imaging of GRPR and PSMA expression in PCa shortly after administration.

Clinical Staging/Diagnostic Imaging in Salvage Therapy for Prostate Cancer

2020 ◽  
pp. 75-78
Author(s):  
Carla Perna ◽  
Jennifer Uribe ◽  
Santiago Uribe-Lewis ◽  
Stephen E. M. Langley
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Imaging ◽  
Salvage Therapy ◽  
Clinical Staging
Sign in / Sign up

Export Citation Format

Share Document